EAM Investors’s Rocket Pharmaceuticals RCKT Stock Holding History

EAM Investors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-32,625	Closed	-$1.45M	–	407
2021 Q1	$1.45M	Buy	32,625 +2,980	+10%	+$164K	0.22%	228
2020 Q4	$1.63M	Buy	+29,645	New	+$1.08M	0.27%	176
2016 Q1	–	Sell	-32,228	Closed	-$1.46M	–	332
2015 Q4	$1.46M	Buy	32,228 +7,371	+30%	+$321K	0.19%	208
2015 Q3	$935K	Buy	+24,857	New	+$1.14M	0.15%	267

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EAM Investors's RCKT Position: Q2 2021 in Review

EAM Investors sold out of Rocket Pharmaceuticals (RCKT) in Q2 2021, closing a stake of 32,625 shares — an estimated $1.45M sold.

EAM Investors first reported a position in RCKT in Q3 2015 and held it in 4 quarters. The position peaked at $1.63M in Q4 2020. 150 funds tracked by Wall St. Rank hold RCKT as of Q2 2021.

EAM Investors reported no remaining Rocket Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
EAM Investors sold 32,625 Rocket Pharmaceuticals shares in Q2 2021, an estimated $1.45M.
EAM Investors first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 4 quarters.
EAM Investors's Rocket Pharmaceuticals position peaked at $1.63M in Q4 2020.
150 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2021.

Based on EAM Investors's 13F filing for Q2 2021, filed 13 Aug 2021.